Dr. Lipo+

Dr. Lipo+ is a BNCÉRA product family marketed for localized fat reduction. The name covers at least three formulations: DR.LIPO+, DR.LIPO+ V, and Prime DR.LIPO+. They differ in declared ingredients, vial volume, and commercial positioning, so Dr. Lipo+ alone is not a complete product identity.

BNCÉRA’s 2026 catalog provides a useful current family map, but it does not disclose active-ingredient concentrations, a complete formula for each presentation, a regulator-hosted authorization, or a clearly identified legal manufacturer. Those gaps should remain visible rather than being filled from reseller listings.

Quick reference

Variant	Manufacturer-declared main ingredients	Presentation	Commercial positioning
DR.LIPO+	Phosphatidylcholine (PPC) + sodium deoxycholate	10 mL × 10 vials	Body-oriented fat-dissolving solution
DR.LIPO+ V	PPC + sodium deoxycholate	5 mL × 10 vials	Face-oriented variant
Prime DR.LIPO+	PPC + carnitine	2 mL × 10 vials	Separate small-vial formulation

Source: BNCÉRA 2026 product catalog 🔗. These are company-declared product facts, not independent compositional analysis or regulatory authorization.

The family name does not define one formula

The current catalog presents the original and V variants as PPC/sodium-deoxycholate formulations. Prime DR.LIPO+ instead lists PPC and carnitine as its main ingredients and does not list sodium deoxycholate in the compact specification.

This makes several common shortcuts unsafe:

• do not assume that Prime is a smaller vial of the original formula
• do not carry the original 10 mL presentation over to DR.LIPO+ V
• do not assume that a face label establishes approval for facial or submental injection
• do not infer active concentration from the vial volume
• do not transfer Kybella’s 10 mg/mL DCA concentration to any Dr. Lipo+ variant

The catalog also discusses peptides, glutathione, vitamin C, adenosine, arginine, arbutin, SP1-EGF, and SP1-FGF1 around the product-family presentation. It does not provide a complete quantitative ingredient table tying every listed component to every variant. These ingredients therefore should not be represented as one confirmed shared formula.

Concentration and finished-product specification

The reviewed current catalog does not establish:

• quantitative PPC concentration
• quantitative sodium-deoxycholate concentration
• whether DCA in explanatory graphics refers to free deoxycholic acid or sodium deoxycholate in the finished product
• complete excipient and preservative lists by variant
• pH, osmolality, sterility, or endotoxin specifications
• a regulator-hosted label or instructions for use
• a stable national authorization number for the product as an injectable medicine

Some distributor pages and older brochures provide longer ingredient lists or numerical claims. They should be treated as leads until matched to the exact current variant, lot, controlling manufacturer document, and local authorization.

Company and brand history

BNCÉRA’s catalog describes the company history as follows:

Date	Company-reported event
May 17, 2018	BNC Global established
2020	DR.LIPO+ launched
2023	Prime DR.LIPO+ launched
2026	Company rebranded from BNC Global to BNCÉRA and opened a new GMP manufacturing facility

The catalog identifies a head office in the Songdo Bio Cluster and a manufacturing-facility address in Incheon. This supports a brand-company and facility relationship. It does not, without a controlling product label or license, establish that BNCÉRA is the legal or physical manufacturer of every Dr. Lipo+ variant and export-market presentation.

Use the narrowest roles supported by the document:

Role	Supported relationship
Current brand and commercial company	BNCÉRA
Former company name	BNC Global
Product-family launches	Reported by BNCÉRA for DR.LIPO+ and Prime DR.LIPO+
Legal manufacturer	Not established in the reviewed public product documentation
Marketing-authorization holder	Not established for a major reference market
Local distributor	Market-specific

Regulatory status

The BNCÉRA catalog states that DR.LIPO+ was registered in Azerbaijan in 2022. It does not identify the registration category, number, intended route, authorized indication, responsible authority, or current status. That company-reported milestone should not be rewritten as broad regulatory approval.

No regulator-hosted approval reviewed for this page established Dr. Lipo+ as an authorized fat-reduction injectable drug in the United States, Canada, the European Union, South Korea, or China. In the United States, FDA states that Kybella is the only FDA-approved fat-dissolving injectable drug and limits that approval to adult submental fat (FDA safety communication 🔗).

This supports not FDA approved in the United States; it does not establish the product’s status in every country. Each market requires its own medicine, device, or other classification record.

Professional packaging is not authorization

A vial presentation, professional-use positioning, a company facility, export history, or a registered milestone without an identifiable record does not establish authorization for injection in the reader’s jurisdiction.

Mechanism and evidence boundary

BNCÉRA describes lysis of adipocytes and a sequence of inflammatory clearance and tissue restructuring. Those are manufacturer mechanism claims. The catalog does not provide product-specific peer-reviewed trials establishing efficacy, comparative performance, or an adverse-event rate for each variant.

Do not use ingredient overlap to claim that DR.LIPO+ or DR.LIPO+ V:

• is equivalent to Kybella, Belkyra, V-OLET, or Rongzhi
• shares an approved submental indication
• has the same cytolytic exposure per milliliter
• is safer because it contains PPC, peptides, vitamins, or other adjunct ingredients
• produces skin tightening, collagen recovery, or reduced inflammation as a proven clinical outcome

Marketing statements about detoxification, regeneration, or natural elimination should be rewritten as manufacturer claims rather than clinical facts.

Practitioner interpretation

When documenting this family, record the full variant name, package volume and vial count, complete ingredient panel on the supplied product, lot, expiry, supplier, storage history, and the specific local authorization relied upon. If concentration and legal manufacturer cannot be verified, retain those as material uncertainties.

Commercial catalogs may include session counts, intervals, treatment maps, or broad body-area claims. They are not reproduced here because a current regulator-hosted label and product-specific authorization context were not established.

Nearby reference pages

• Terminology and mechanisms separates PPC/deoxycholate mixtures from approved DCA medicines.
• DCA drugs vs PPC/deoxycholate mixtures explains why ingredient overlap does not establish product equivalence.
• Lipo Lab is another multi-variant commercial family with incomplete quantitative specifications.
• Regional regulation places US approval and other national records in their proper jurisdiction.